Allogene Therapeutics, Inc. (ALLO) P/E Ratio

Allogene Therapeutics, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

• Allogene Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -4.33, a change of -3.27 year-over-year.
• Allogene Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -3.44, a change of -2.17 year-over-year.
• Allogene Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -1.64, a change of 0.11 year-over-year.
• Allogene Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -1.31, a change of 0.76 year-over-year.
• Allogene Therapeutics, Inc. pe ratio for fiscal 2026 was -4.33.
• Allogene Therapeutics, Inc. pe ratio for fiscal 2025 was -1.64, a change of 0.11 from fiscal 2024.
• Allogene Therapeutics, Inc. pe ratio for fiscal 2024 was -1.75, a change of -0.1 from fiscal 2023.
• Allogene Therapeutics, Inc. pe ratio for fiscal 2023 was -1.65, a change of 1.06 from fiscal 2022.